Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma

Jia,Xiaobo; Gao,Yingtang; Zhai,Daokuan; Liu,Jiao; Wang,Yajie; Jing,Li; Du,Zhi

doi:10.3892/ol.2015.3050

Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma

Authors:
- Xiaobo Jia
- Yingtang Gao
- Daokuan Zhai
- Jiao Liu
- Yajie Wang
- Li Jing
- Zhi Du
View Affiliations

Affiliations: Third Central Clinical College, Tianjin Medical University, Tianjin 300170, P.R. China, Key Laboratory of Artificial Cell, Institute of Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin Medical University, Tianjin 300170, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/ol.2015.3050
Pages: 2347-2352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin expression in the serum of patients with hepatocellular carcinoma (HCC) and nonmalignant chronic liver diseases remain to be elucidated. The aims of the present study were to evaluate the diagnostic role of survivin in the serum of patients with HCC and identify which ELISA kit performed best in detecting the levels of serum survivin. In total, 80 patients were included in the present study, including 20 patients with HCC, 20 patients with liver cirrhosis, 20 patients with chronic hepatitis B virus infection and 20 healthy volunteers. The levels of survivin protein in the serum were detected using two different ELISA kits (R&D and Abnova). The positive ratios of serum survivin detected by the R&D ELISA kit in all the cases were 8.75% (7/80; median, 0 pg/ml; range, 0‑39.8 pg/ml) and in HCC patients were 5% (1/20; median, 0 pg/ml; range, 0-39.8 pg/ml). For the same samples analyzed using the Abnova ELISA kit, the positive ratios of serum survivin in all the cases were 22.5% (18/80; median, 0 pg/ml; range, 0‑553.5 pg/ml) and in HCC patients were 25% (5/20; median, 0 pg/ml; range, 0‑93.5 pg/ml). The results obtained by the different ELISA kits demonstrated no statistically significant differences in the level of survivin between HCC patients and healthy controls. The correlation coefficient was 0.0064 (P=0.481) when analyzing the same serum samples with the different ELISA kits. In addition, the highest positive ratio of serum survivin was observed using the Abnova kit. A statistically significant difference in the results was observed between the R&D and Abnova kits. In general, the levels and positive ratios of serum survivin in the patients with HCC were significantly low. Furthermore, no difference was observed between HCC patients and controls in regard to the levels of serum survivin detected by the R&D and Abnova ELISA kits. In conclusion, survivin is unlikely to be a promising serological maker for the diagnosis of HCC.

View Figures

View References

1	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 15:(Suppl 4). 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
2	Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 12:1175–1181. 2006.PubMed/NCBI
3	Spangenberg HC, Thimme R and Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis. 26:385–390. 2006. View Article : Google Scholar : PubMed/NCBI
4	Nikolovska-Coleska Z, Meagher JL, Jiang S, et al: Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. Biochemistry. 47:9811–9824. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lens SM, Rodriguez JA, Vader G, et al: Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell. 17:1897–1909. 2006. View Article : Google Scholar : PubMed/NCBI
6	Vischioni B, van der Valk P, Span SW, et al: Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol. 37:78–86. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ito T, Shiraki K, Sugimoto K, et al: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 31:1080–1085. 2000. View Article : Google Scholar : PubMed/NCBI
8	Yang Y, Zhu J, Gou H, et al: Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 28:796–803. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zhu H, Chen XP, Zhang WG, et al: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol. 11:3855–3859. 2005.PubMed/NCBI
10	Hui WT, Zan Y, Wang XJ, et al: Expression of survivin, p53 and its relationship with apoptosis, proliferation in hepatocellular carcinoma (HCC). JNMU. 22:255–259. 2008.
11	Chau GY, Lee AF, Tsay SH, et al: Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology. 51:204–218. 2007. View Article : Google Scholar : PubMed/NCBI
12	Augello C, Caruso L, Maggioni M, et al: Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 9:1252009. View Article : Google Scholar : PubMed/NCBI
13	El-Attar HA, Kandil MH, El-Kerm YM and El-Ghandour MK: Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev. 11:897–903. 2010.PubMed/NCBI
14	Matteucci C, Sorrentino R, Bellis L, et al: Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. Hepatol Res. 44:1008–1018. 2014. View Article : Google Scholar : PubMed/NCBI
15	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
16	Llovet JM, Brú C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
17	Moon WS and Tarnawski AS: Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol. 34:1119–1126. 2003. View Article : Google Scholar : PubMed/NCBI
18	Takashima H, Nakajima T, Moriguchi M, et al: In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 25:77–84. 2005. View Article : Google Scholar : PubMed/NCBI
19	Morinaga S, Nakamura Y, Ishiwa N, et al: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep. 12:1189–1194. 2004.PubMed/NCBI
20	Montorsi M, Maggioni M, Falleni M, et al: Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology. 54:2040–2044. 2007.PubMed/NCBI
21	Zhang JY, Megliorino R, Peng XX, et al: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol. 46:107–114. 2007. View Article : Google Scholar : PubMed/NCBI
22	Megliorino R, Shi FD, Peng XX, et al: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 29:241–248. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yagihashi A, Asanuma K, Kobayashi D, et al: Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity. 38:445–448. 2005. View Article : Google Scholar : PubMed/NCBI